Medicus Pharma (NASDAQ:MDCX) Price Target Raised to $27.00

Medicus Pharma (NASDAQ:MDCX) had its price target boosted by D. Boral Capital from $14.00 to $27.00 in a research note published on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on the company. D Boral Capital raised Medicus Pharma to a “strong-buy” rating in a report on Monday, April 14th. Maxim Group boosted their price objective on shares of Medicus Pharma from $10.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th.

Medicus Pharma Stock Up 14.9%

Shares of MDCX opened at $6.32 on Monday. The firm has a 50-day moving average price of $3.81. Medicus Pharma has a 12-month low of $1.80 and a 12-month high of $6.98.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). Equities research analysts anticipate that Medicus Pharma will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Private Advisor Group LLC purchased a new stake in Medicus Pharma Ltd. (NASDAQ:MDCX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 56,750 shares of the company’s stock, valued at approximately $211,000. Private Advisor Group LLC owned 0.42% of Medicus Pharma as of its most recent filing with the Securities & Exchange Commission.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.